#USA #Drug Development #Peachtree Corners #RayBiotech #Venebio

RayBiotech and Venebio Collaboration Overview

On June 25, 2025, RayBiotech Life, Inc., an internationally recognized leader in the fields of proteomics and translational research tools, announced a significant strategic partnership with Venebio Group, LLC. Renowned for its regulatory strategy expertise and drug safety analytics, Venebio seeks to further bolster the developmental stages of pharmaceuticals and diagnostic solutions. This collaborative effort is set to transform how these products reach the market, ensuring they meet both clinical needs and regulatory standards effectively.

Strengthening Development Through Synergy

The collaboration is formalized through a newly established Master Services Agreement (MSA). By merging RayBiotech’s innovative proteomics platforms and biomarker discovery services with Venebio's deep-rooted knowledge in regulatory planning, trial design, and evidence generation, the partnership promises to streamline the paths for drug and diagnostics developers.

Dr. Jarad Wilson, Associate Director of Business Development at RayBiotech, highlighted the importance of this synergy: "This partnership creates a powerful synergy between RayBiotech's cutting-edge technologies and Venebio's proven leadership in regulatory and clinical strategy. Together, we aim to streamline the development of impactful therapeutics and diagnostics, particularly in areas of high unmet medical need."

Expertise and Innovation Meet

Venebio Group, based in Virginia, is celebrated for its successful support of biopharma innovators throughout the entire lifecycle of drug development. Their proficiency spans from the initial discovery phase to post-market safety evaluation and reporting. The company's regulatory insights and strategic support services are expected to enrich RayBiotech's offerings in various high-throughput areas, including protein arrays, cytokine profiling, and antibody development.

According to Catherine C. Vick, MS, President and CEO of Venebio Group, the partnership enhances the comprehensive support available to clients: "RayBiotech's capabilities in translational biomarker discovery and clinical assay development are ideal complements to our consulting practice."

Advantages for Life Science Companies

This collaboration aims to provide tailored services that encompass everything from biomarker-driven trial design to clinical assay validation. By merging their strengths, the partnership seeks to simplify the process for life science companies, helping them navigate the complex regulatory landscape while demonstrating the therapeutic value of their offerings.

RayBiotech Life, Inc. and Venebio Group present a united front, combining top-tier scientific and regulatory expertise to enhance the efficiency and effectiveness of drug and diagnostic development. Clients can look forward to a more streamlined approach to meeting the rigorous demands of both developers and the regulatory environment.

About RayBiotech Life, Inc.

RayBiotech is recognized as a leader in the proteomics sector, delivering advanced tools and services that foster discovery in disease biology, biomarker validation, and therapeutic development. The company’s portfolio includes antibody arrays, ELISA kits, custom assay development, and central lab services specifically designed to cater to translational and clinical research needs.

About Venebio Group, LLC

Venebio Group is a specialized scientific consultancy that provides strategic organizational support to pharmaceutical, biotechnology, and medical device firms. Their extensive expertise encompasses regulatory affairs, clinical trial design, data science, epidemiology, pharmacovigilance, and market access strategies, all tailored towards high-impact therapies.

Media Contact Information

For further inquiries, please reach out to:
Valerie Jones, Ph.D.
Phone: 770-729-2992

This collaboration between RayBiotech and Venebio is poised to significantly enhance the landscape of drug development and diagnostics, making impactful therapies more accessible to those in need.